Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

This study has been completed.
Sponsor:
Collaborator:
University of Copenhagen
Information provided by:
University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov Identifier:
NCT00732602
First received: August 11, 2008
Last updated: February 12, 2009
Last verified: February 2009

August 11, 2008
February 12, 2009
January 2008
August 2008   (final data collection date for primary outcome measure)
plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min. [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00732602 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in patients with type 1 diabetes mellitus.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
Diabetes Mellitus
  • Other: GIP-infusion
  • Other: Sodium-chloride
  • Other: GLP-2 infusion
  • Active Comparator: B
    GLP-2 infusion
    Intervention: Other: GLP-2 infusion
  • Placebo Comparator: C
    Sodium-chloride infusion
    Intervention: Other: Sodium-chloride
  • Active Comparator: A
    GIP-infusion
    Intervention: Other: GIP-infusion
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
8
Not Provided
August 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Caucasians over 18 years with type 1 diabetes (WHO criteria)
  • Arginine test without rise in plasma C-peptide
  • Normal blood Hemoglobin
  • Informed consent

Exclusion Criteria:

  • Liver disease
  • Diabetic nephropathy
  • Treatment with medications unpausable for 12 hours
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00732602
H-D-2007-0058
No
Mikkel Christensen MD, University Hospital, Gentofte, Copenhagen
University Hospital, Gentofte, Copenhagen
University of Copenhagen
Not Provided
University Hospital, Gentofte, Copenhagen
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP